Submissions for variant NM_005609.4(PYGM):c.148C>T (p.Arg50Ter)

gnomAD frequency: 0.00181  dbSNP: rs116987552

Total submissions: 34

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000081306	SCV000329478	pathogenic	not provided	2019-10-31	criteria provided, single submitter	clinical testing	Mouse model, homozygous for R50X, found to have undetectable myophosphorylase protein and enzyme activity in skeletal muscle as well as massive muscle glycogen accumulation (Brull et al., 2015); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25873271, 31980526, 32124677, 31517061, 29961518, 30609409, 30316539, 30415384, 29382405, 22995991, 22344438, 20981092, 18667317, 10918252, 9120482, 27899787, 27300253, 26670295, 27031745, 22730558, 27030740, 22818872, 8316268, 17404776, 25741863, 26240973, 25240406, 25914343, 23653251)
Illumina Laboratory Services, Illumina	RCV000002388	SCV000373042	pathogenic	Glycogen storage disease, type V	2017-04-27	criteria provided, single submitter	clinical testing	The PYGM c.148C>T (p.Arg50Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. The p.Arg50Ter variant is the most commonly identified variant in patients with glycogen storage disease type V, also known as McArdle disease, in the majority of populations studied (Martin et al. 2006; Nogales-Gadea et al. 2015). Across a selection of the available literature, the p.Arg50Ter variant is detected with an allele frequency ranging from 43%-78% in the respective patient cohorts (Tsujino et al. 1993; Bruno et al. 2006; Aquaron et al. 2007; Deschauer et al. 2007; Vieitez et al. 2011; Gurgel-Giannetti et al. 2013). The variant was absent from 96 healthy individuals but is reported at a frequency of 0.00314 in the European American population of the Exome Sequencing Project. A knock-in mouse model homozygous for the p.Arg50Ter variant displays a McArdle disease-like phenotype (Nogales-Gadea et al. 2012). Based on the collective evidence, the p.Arg50Ter variant is classified as pathogenic for glycogen storage disease type V. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Counsyl	RCV000002388	SCV000485127	pathogenic	Glycogen storage disease, type V	2016-03-08	criteria provided, single submitter	clinical testing
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics	RCV000081306	SCV000511631	pathogenic	not provided	2016-07-06	criteria provided, single submitter	clinical testing
Molecular Diagnostics Lab, Nemours Children's Health, Delaware	RCV000002388	SCV000590832	pathogenic	Glycogen storage disease, type V	2016-01-12	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV000002388	SCV000626780	pathogenic	Glycogen storage disease, type V	2024-01-31	criteria provided, single submitter	clinical testing	This sequence change creates a premature translational stop signal (p.Arg50*) in the PYGM gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PYGM are known to be pathogenic (PMID: 8316268, 16786513). This variant is present in population databases (rs116987552, gnomAD 0.3%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individual(s) with McArdle disease (PMID: 8316268, 16786513, 21802952, 22250184, 23653251). ClinVar contains an entry for this variant (Variation ID: 2298). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects PYGM function (PMID: 22730558). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000002388	SCV000713109	pathogenic	Glycogen storage disease, type V	2018-06-27	criteria provided, single submitter	clinical testing	The p.Arg50X variant in PYGM is a known pathogenic variant that has been report ed in at least 50 homozygotes and 29 compound heterozygous with glycogen storage disease type V (GSDV), also known as McArdle disease, and segregated with disea se in 5 affected siblings from 4 families (Tsujino 1993, Gurgel-Giannetti 2013, deLuna 2014, and Hongrel 2015). Mouse models demonstrate that this variant cause s glycogen storage disease type V (Nogales-Gadea 2012 and Brull 2015). It has al so been reported in ClinVar (Variation ID 2298) by multiple laboratories as path ogenic and has been identified in 0.20% (318/126684) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). This frequency is low enough to be co nsistent with a recessive carrier frequency. In summary, this variant meets crit eria to be classified as pathogenic for autosomal recessive GSDV based upon case observations, segregation studies, and animal models. ACMG/AMP Criteria applied : PVS1, PM3_Very Strong, PS3, PP1_Strong.
Ambry Genetics	RCV000622729	SCV000740891	pathogenic	Inborn genetic diseases	2014-09-07	criteria provided, single submitter	clinical testing
Fulgent Genetics, Fulgent Genetics	RCV000002388	SCV000893906	pathogenic	Glycogen storage disease, type V	2022-05-04	criteria provided, single submitter	clinical testing
CeGaT Center for Human Genetics Tuebingen	RCV000081306	SCV001247785	pathogenic	not provided	2023-03-01	criteria provided, single submitter	clinical testing	PYGM: PM3:Very Strong, PVS1, PM2, PS3:Supporting
Clinical Genetics and Genomics, Karolinska University Hospital	RCV000081306	SCV001449610	pathogenic	not provided	2015-10-29	criteria provided, single submitter	clinical testing
Mayo Clinic Laboratories, Mayo Clinic	RCV000081306	SCV001714990	pathogenic	not provided	2021-11-22	criteria provided, single submitter	clinical testing	PM2, PVS1
Revvity Omics, Revvity	RCV000002388	SCV002019575	pathogenic	Glycogen storage disease, type V	2024-01-05	criteria provided, single submitter	clinical testing
DASA	RCV000002388	SCV002107134	pathogenic	Glycogen storage disease, type V	2022-03-05	criteria provided, single submitter	clinical testing	The c.148C>T;p.(Arg50*) variant creates a premature translational stop signal in the PYGM gene. It is expected to result in an absent or disrupted protein product - PVS1. This sequence change has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 2298; PMID: 20301518; PMID: 23653251; PMID: 17324573; PMID: 12929201; PMID:20301518) - PS4. The variant is present at low allele frequencies population databases (rs116987552 – gnomAD 0.01499%; ABraOM 0.001708 frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Arg50*) was detected in trans with a pathogenic variant (PMID: 23653251; PMID: 17324573) - PM3. In summary, the currently available evidence indicates that the variant is pathogenic.
Molecular Genetics, Royal Melbourne Hospital	RCV000002388	SCV002503615	pathogenic	Glycogen storage disease, type V	2022-04-22	criteria provided, single submitter	clinical testing	This sequence change creates a premature termination codon at position 50 in exon 1 (of 20) of PYGM, p.(Arg50*). This alteration is expected to result in nonsense-mediated decay in a gene where loss of function is a known mechanism of disease. The variant is present in a large population cohort at a frequency of 0.15% (rs116987552, 424/282,854 alleles, 0 homozygotes in gnomAD v2.1), and is the most common pathogenic variant associated with glycogen storage disease type V (also known as McArdle disease) in the European population. The variant has been identified as homozygous and compound heterozygous with a second pathogenic allele in many cases with a clinical diagnosis of McArdle disease (PMID: 8316268). Based on the classification scheme RMH ACMG Guidelines v1.2.1, this variant is classified as PATHOGENIC. Following criteria are met: PVS1, PM3_VeryStrong.
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein	RCV002251857	SCV002523722	pathogenic	See cases	2020-06-24	criteria provided, single submitter	clinical testing	ACMG classification criteria: PVS1, PS3, PS4, PM3, PP1
MGZ Medical Genetics Center	RCV000002388	SCV002580462	pathogenic	Glycogen storage disease, type V	2021-10-13	criteria provided, single submitter	clinical testing
Genetics and Molecular Pathology, SA Pathology	RCV000002388	SCV002761410	pathogenic	Glycogen storage disease, type V	2021-12-06	criteria provided, single submitter	clinical testing	The PYGM c.148C>T variant is classified as Pathogenic (PVS1, PS3, PS4, PM3) The PYGM c.148C>T variant is a single nucleotide change which is predicted to result in premature termination of the protein product at codon 50 (PVS1). The variant has been reported in probands with a clinical presentation of OMIM:232600 ( Reported multiple times in OMIM:608455 ) (PS4). Well-established functional studies show a deleterious effect of this variant ( Nogales-Gadea (2012) PubMed: 22730558 Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease ) (PS3). This variant has been detected in trans with a pathogenic variant for this recessive condition (PM3). Identified in another case as compound het with a second pathogenic variant in PYGM (c.613G>A;p.Gly205Ser). This variant was shown to be maternally inherited and the c.613G>A variant is paternally inherited in that case. The variant has been reported in dbSNP (rs116987552) and in the HGMD database: CM930629. It has been reported as Pathogenic by other diagnostic laboratories (ClinVar Variation ID: 2298).
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute	RCV000002388	SCV002767308	pathogenic	Glycogen storage disease, type V	2020-10-19	criteria provided, single submitter	clinical testing	Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with McArdle disease (MIM#232600). (I) 0106 - This gene is associated with autosomal recessive disease. However, a single family has been reported for an autosomal dominant glycogen storage disorder (PMID: 32386344). (I) 0115 - Variants in this gene are known to have variable expressivity. Some affected individuals have minimal symptoms with essentially no limitations in activities of daily living. This may be attributed to variable physical activity habits (Gene Reviews). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 for a recessive condition (v3: 253 heterozygotes, 1 homozygotes). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. Several NMD-predicted variants have been reported in patients with McArdle disease (MIM#232600) (ClinVar). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported in several McArdle disease (MIM#232600) patients in both homozygous and compound heterozygous states (ClinVar; PMID: 29143597). (SP) 1205 - This variant has been shown to be maternally inherited (VCGS #20G001969). (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV000002388	SCV004021025	pathogenic	Glycogen storage disease, type V	2023-06-22	criteria provided, single submitter	clinical testing	Variant summary: PYGM c.148C>T (p.Arg50X) results in a premature termination codon, predicted to cause absence of the protein due to nonsense mediated decay, which is a commonly known mechanism for disease. The variant allele was found at a frequency of 0.0015 in 251452 control chromosomes in gnomAD. This frequency is not significantly higher than estimated for a pathogenic variant in PYGM causing Glycogen Storage Disease Type V, also known as McArdle disease, (0.0015 vs 0.0035), allowing no conclusion about variant significance. c.148C>T has been reported in the literature in individuals affected with Glycogen Storage Disease Type V (example: Cerino_2022). These data indicate that the variant is very likely associated with disease. The following publication have been ascertained in the context of this evaluation (PMID: 35741838). Twenty submitters have cited clinical-significance assessments (all pathogenic) for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic.
Institute of Human Genetics, Clinical Exome/Genome Diagnostics Group, University Hospital Bonn	RCV000002388	SCV004032465	pathogenic	Glycogen storage disease, type V	2023-02-01	criteria provided, single submitter	clinical testing
Baylor Genetics	RCV000002388	SCV004207202	pathogenic	Glycogen storage disease, type V	2024-03-30	criteria provided, single submitter	clinical testing
Clinical Genetics Laboratory, Skane University Hospital Lund	RCV000081306	SCV005197312	pathogenic	not provided	2023-12-13	criteria provided, single submitter	clinical testing
Institute of Immunology and Genetics Kaiserslautern	RCV000002388	SCV005382156	pathogenic	Glycogen storage disease, type V	2023-07-19	criteria provided, single submitter	clinical testing	ACMG Criteria: PVS1, PS3, PS4, PM3, PP1, PP5; Variant was found in compound heterozygous state with NM_005609.4:c.1477del.
OMIM	RCV000002388	SCV000022546	pathogenic	Glycogen storage disease, type V	2007-07-01	no assertion criteria provided	literature only
GeneReviews	RCV000002388	SCV000172194	not provided	Glycogen storage disease, type V		no assertion provided	literature only
Natera, Inc.	RCV000002388	SCV001454306	pathogenic	Glycogen storage disease, type V	2020-09-16	no assertion criteria provided	clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System	RCV000081306	SCV001554240	pathogenic	not provided		no assertion criteria provided	clinical testing	The PYGM p.R50* variant is a well-known pathogenic variant known to cause McArdle disease and is the most common pathogenic variant in individuals of European and US descent (Martin_2019_PMID:20301518). The variant was identified in dbSNP (ID: rs116987552), ClinVar (classified as pathogenic by Counsyl, Ambry Genetics, GeneDx, EGL Genetic Diagnostics, Invitae, Laboratory for Molecular Medicine, Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics, Fulgent Genetics, Illumina and Molecular Diagnostics Lab, Nemours Alfred I. duPont Hospital for Children) and LOVD 3.0 (classified as pathogenic). The variant was identified in control databases in 424 of 282854 chromosomes at a frequency of 0.001499 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (non-Finnish) in 325 of 129154 chromosomes (freq: 0.002516), Other in 18 of 7226 chromosomes (freq: 0.002491), Latino in 48 of 35440 chromosomes (freq: 0.001354), African in 18 of 24972 chromosomes (freq: 0.000721), European (Finnish) in 12 of 25122 chromosomes (freq: 0.000478), Ashkenazi Jewish in 1 of 10370 chromosomes (freq: 0.000096), East Asian in 1 of 19954 chromosomes (freq: 0.00005), and South Asian in 1 of 30616 chromosomes (freq: 0.000033). The c.148C>T variant leads to a premature stop codon at position 50 which is predicted to lead to a truncated or absent protein and loss of function. Loss of function variants of the PYGM gene are an established mechanism of disease in McArdle disease and is the type of variant known to cause the disorder in the homozygous or compound heterozygous state. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. Mouse models with the p.R50* variant display a McArdle disease phenotype (Nogales-Gadea_2012_PMID:22730558; Brull_2015_PMID: 25873271). In summary, based on the above information this variant meets our laboratory’s criteria to be classified as pathogenic.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen	RCV000081306	SCV001742786	pathogenic	not provided		no assertion criteria provided	clinical testing
Genomics England Pilot Project, Genomics England	RCV000002388	SCV001760270	likely pathogenic	Glycogen storage disease, type V		no assertion criteria provided	clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center	RCV000081306	SCV001807182	pathogenic	not provided		no assertion criteria provided	clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center	RCV000081306	SCV001969198	pathogenic	not provided		no assertion criteria provided	clinical testing
Columbia University Laboratory of Personalized Genomic Medicine, Columbia University Medical Center	RCV001730469	SCV001980710	pathogenic	Muscular atrophy	2021-10-18	no assertion criteria provided	clinical testing	The c.148C>T (p.Arg50Ter) variant in PYGM identified in this individual is one of the most common, well established, pathogenic variants described in PYGM (Nogales-Gadea et al., 2015). To date, this variant has eleven independent pathogenic curations in ClinVar (VarID:2298). Sequencing and RT-PCR studies have suggested that the c.148C>T variant is subject to nonsense mediated decay as mature cDNA transcript were not detected from this allele in individuals harboring these variant (Nogales-Gadea et al., 2008).
Practice for Gait Abnormalities, David Pomarino, Competency Network Toe Walking c/o Practice Pomarino	RCV003319158	SCV004023192	likely pathogenic	Tip-toe gait	2022-12-19	no assertion criteria provided	clinical testing	Toe Walking has various causes, ranging from idiopathic or habitual reasons to an underlying neuromuscular disease. The most observed form of toe walking is idiopathic toe walking (ITW) - a diagnosis of exclusion. ITW occurs in about 5% of children after their second birthday and is a common problem in pediatric orthopedics. In about 70% of these cases, there is spontaneous remission within six months of the onset of ITW. If the toe walk persists, one can assume the presence of a non-idiopathic form of toe walk (n-ITW). In n-ITW, the causes of the abnormal gait are neurological or myogenic. Differential diagnoses such as infantile cerebral palsy, muscular dystrophy, spinal amyotrophy and hereditary motor-sensory neuropathy as well as rare metabolic disorders of the musculature must be considered (Pomarino et al., 2018). In our clinical ITW consultation, we screen children with n-ITW for a genetic form of tiptoe gait using next generation sequencing for gene variants in 49 genes. These are genes in which gene variants can lead to neuromuscular diseases in which an association with toe-tapping gait has been reported or can be suspected due to patients’ clinical symptoms. To the best of our knowledge, this is the first study in which several patients with toe walking displayed heterozygosity for pathogenic or likely pathogenic PYGM mutations and mild symptoms of the metabolic muscle disease McArdle. The findings of our research are in line with recently published observations in heterozygous family members patients with McArdle disease. We should mention that some of the patients in our cohort harbored heterozygous variants in other genes of our gene panel. However, the numbers in this study were too small to workout any resulting combined genetic effects. It is concluded that genetic conditions can contribute to the development of toe walking. Apparently, even a slight genetic weakening of the muscles can lead to changes to the gait pattern. Future studies must show how the pathomechanism can be explained for the PYGM variants and whether there are new therapeutic approaches to be developed based on this research.